Literature DB >> 26154003

The constrained prescription, interchangeability and substitution of biosimilars.

Paola Minghetti1, Paolo Rocco1, Huub Schellekens2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26154003     DOI： 10.1038/nbt.3272

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  Biosimilars and regulatory authorities.

Authors:  Paola Minghetti; Paolo Rocco; Lucia Del Vecchio; Francesco Locatelli
Journal:  Nephron Clin Pract       Date:  2010-08-03

2.  Clinical comparability and European biosimilar regulations.

Authors:  Huub Schellekens; Ellen Moors
Journal:  Nat Biotechnol       Date:  2010-01       Impact factor: 54.908

Review 3.  The regulatory framework of biosimilars in the European Union.

Authors:  Paola Minghetti; Paolo Rocco; Francesco Cilurzo; Lucia Del Vecchio; Francesco Locatelli
Journal:  Drug Discov Today       Date:  2011-08-12       Impact factor: 7.851

4.  Interchangeability, immunogenicity and biosimilars.

Authors:  Hans C Ebbers; Stacy A Crow; Arnold G Vulto; Huub Schellekens
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

5.  Biosimilar therapeutics-what do we need to consider?

Authors:  Huub Schellekens
Journal:  NDT Plus       Date:  2009-01
  5 in total
  5 in total

Review 1.  Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

Authors:  Carolyn Tieu; Eleanor J Lucas; Mindi DePaola; Lori Rosman; G Caleb Alexander
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

Review 2.  Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil.

Authors:  Marcos Renato de Assis; Valdair Pinto
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-10-31       Impact factor: 5.346

3.  Cell line access to revolutionize the biosimilars market.

Authors:  Dzintars Gotham
Journal:  F1000Res       Date:  2018-05-03

4.  Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.

Authors:  Valentina Perrone; Stefania Saragoni; Stefano Buda; Alessandro Broccoli; Luca Degli Esposti
Journal:  Biologics       Date:  2016-12-01

5.  Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.

Authors:  Don Husereau; Brian Feagan; Carl Selya-Hammer
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.